Monopar Therapeutics Inc [MNPR] stock is trading at $0.77, up 20.31%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The MNPR shares have gain 20.61% over the last week, with a monthly amount drifted -6.78%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 10, April 2024, Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients. In a post published today on Yahoo Finance, Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that its Phase 1 dosimetry clinical trial for its novel radiopharmaceutical imaging agent MNPR-101-Zr (MNPR-101 conjugated to zirconium-89) is now active and recruiting patients with advanced cancers. The antibody MNPR-101 targets the urokinase plasminogen activator receptor (uPAR), which is expressed on numerous tumor types including pancreatic, breast, colorectal, and bladder.
From an analyst’s perspective:
Monopar Therapeutics Inc [NASDAQ: MNPR] stock has seen the most recent analyst activity on January 28, 2021, when ROTH Capital initiated its Buy rating and assigned the stock a price target of $49.
Monopar Therapeutics Inc [MNPR] stock has fluctuated between $0.27 and $1.75 over the past year. Monopar Therapeutics Inc [NASDAQ: MNPR] shares were valued at $0.77 at the most recent close of the market.
Analyzing the MNPR fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -1.13, Equity is -1.15 and Total Capital is -1.58.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.7100 points at the first support level, and at 0.6500 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.8400, and for the 2nd resistance point, it is at 0.9100.
Monopar Therapeutics Inc [MNPR] reported earnings per share of -$0.12 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.15/share, meaning a difference of $0.03 and a surprise factor of 20.00%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.14 per share as compared to estimates of -$0.17 per share, a difference of $0.03 representing a surprise of 17.60%.
Ratios To Look Out For
For context, Monopar Therapeutics Inc’s Current Ratio is 4.17. Further, the Quick Ratio stands at 4.17, while the Cash Ratio is 4.13.
